GlassScriptPhysician profile
Nataia Buza
NPI 1790962017
$29,456.92
in general payments reported to CMS, 2019-2025
8 companies · $27K in 2025
The $27K reported for 2025 was more than what 98% of Anatomic Pathology providers received nationally (typical 2025 total: $110).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170 · 2023: $128 · 2024: $1,969 · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $28K · Travel and Lodging: $783 · Food and Beverage: $744 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $27,605.50 |
| Travel and Lodging | $783.26 |
| Food and Beverage | $744.19 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $153.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $20,900.76 | 2024-2025 | Enhertu |
| Astrazeneca Uk Limited | $6,205.00 | 2025 | |
| Merck Sharp & Dohme LLC | $1,283.00 | 2025 | |
| Agilent Technologies, INC. | $526.15 | 2025 | |
| Foundation Medicine, INC. | $170.12 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $153.85 | 2024 | |
| Immunogen, INC. | $127.71 | 2023 | Elahere |
| Glaxosmithkline, LLC. | $90.33 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nataia Buza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.